November 9, 2018 - Financial News Media

Q BioMed Provides Important Update on QBM001 Developmental Drug Targeting a Non-Verbal and Minimally Verbal Patient Subset on the Autism Spectrum

Company Further Develops Its Autistic Spectrum Disorder (ASD) Drug Technology and Expects Several Development Partnerships In Anticipation of Clinical Program in 2019 NEW YORK, October 9, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to provide an update on QBM001, its Autistic Spectrum Disorder (ASD) drug development program […]

Sign up to stay informed on all the latest Market News Information

FINANCIALNEWSMEDIA.COM (FNM) IS A THIRD PARTY PUBLISHER AND NEWS DISSEMINATION SOLUTIONS PROVIDER OF MULTIMEDIA PLATFORMS THAT ENABLE OFFICERS & DIRECTORS, CORPORATE COMMUNICATORS, PUBLIC RELATIONS AND INVESTOR RELATIONS OFFICERS TO LEVERAGE CONTENT TO ENGAGE WITH ALL THEIR KEY AUDIENCES. ANY IDEAS AND OPINIONS PRESENTED IN ANY FNM NEWS ALERTS, VIDEO CLIPS, PRESS RELEASES, RSS FEEDS OR SOCIAL NETWORK POSTS ARE FOR INFORMATIONAL PURPOSES ONLY, AND DO NOT REFLECT THE OPINIONS OF FNM OR ANY OF ITS AFFILIATES, SUBSIDIARIES OR PARTNERS. UNDER NO CIRCUMSTANCES SHOULD ANY CONTENT CONTAINED HEREIN BE INTERPRETED TO REPRESENT TRADING OR INVESTMENT ADVICE. ALL VIEWERS AGREE THAT UNDER NO CIRCUMSTANCES WILL FNM, ITS SUBSIDIARIES, PARTNERS, OFFICERS, EMPLOYEES, AFFILIATES, OR AGENTS BE HELD LIABLE FOR ANY LOSS OR DAMAGE CAUSED BY YOUR RELIANCE ON INFORMATION CONTAINED ON THIS OR ANY AFFILIATED WEBSITE.